JP2018514558A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018514558A5 JP2018514558A5 JP2017556748A JP2017556748A JP2018514558A5 JP 2018514558 A5 JP2018514558 A5 JP 2018514558A5 JP 2017556748 A JP2017556748 A JP 2017556748A JP 2017556748 A JP2017556748 A JP 2017556748A JP 2018514558 A5 JP2018514558 A5 JP 2018514558A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- group
- composition according
- seq
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 32
- 230000001225 therapeutic effect Effects 0.000 claims description 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 210000002865 immune cell Anatomy 0.000 claims description 11
- 108010047827 Sialic Acid Binding Immunoglobulin-like Lectins Proteins 0.000 claims description 7
- 102000007073 Sialic Acid Binding Immunoglobulin-like Lectins Human genes 0.000 claims description 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims description 3
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims description 3
- 238000000684 flow cytometry Methods 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 3
- 210000000822 natural killer cell Anatomy 0.000 claims description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 34
- 229920001184 polypeptide Polymers 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 229910052698 phosphorus Inorganic materials 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 208000036142 Viral infection Diseases 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000035755 proliferation Effects 0.000 claims 3
- 230000009385 viral infection Effects 0.000 claims 3
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 230000002085 persistent effect Effects 0.000 claims 2
- TYVPVYZUWISNGW-UITIRPQLSA-N (4S,5R,6R)-5-acetyl-5-amino-2,4-dihydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid (2R,3S,4S,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO.C(C)(=O)[C@]1([C@H](CC(C(O)=O)(O)O[C@H]1[C@H](O)[C@H](O)CO)O)N TYVPVYZUWISNGW-UITIRPQLSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 230000006052 T cell proliferation Effects 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 230000009227 antibody-mediated cytotoxicity Effects 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 229930182830 galactose Natural products 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 210000000581 natural killer T-cell Anatomy 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 108020003175 receptors Proteins 0.000 description 20
- 102000005962 receptors Human genes 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 14
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 5
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 102100026292 Asialoglycoprotein receptor 1 Human genes 0.000 description 3
- 101710200897 Asialoglycoprotein receptor 1 Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 102000013361 fetuin Human genes 0.000 description 3
- 108060002885 fetuin Proteins 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000002764 solid phase assay Methods 0.000 description 3
- OIZGSVFYNBZVIK-FHHHURIISA-N 3'-sialyllactose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O OIZGSVFYNBZVIK-FHHHURIISA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- WBSCNDJQPKSPII-KKUMJFAQSA-N Lys-Lys-Lys Chemical group NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O WBSCNDJQPKSPII-KKUMJFAQSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 102100029214 SLAM family member 8 Human genes 0.000 description 2
- 101710083288 SLAM family member 8 Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 102100029957 Sialic acid-binding Ig-like lectin 5 Human genes 0.000 description 2
- 101710110535 Sialic acid-binding Ig-like lectin 5 Proteins 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 238000007398 colorimetric assay Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 102100028681 C-type lectin domain family 4 member K Human genes 0.000 description 1
- 101710183165 C-type lectin domain family 4 member K Proteins 0.000 description 1
- 102100040840 C-type lectin domain family 7 member A Human genes 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 108010021468 Fc gamma receptor IIA Proteins 0.000 description 1
- 102100031513 Fc receptor-like protein 4 Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 101000846909 Homo sapiens Fc receptor-like protein 4 Proteins 0.000 description 1
- 101000863882 Homo sapiens Sialic acid-binding Ig-like lectin 7 Proteins 0.000 description 1
- 101000863883 Homo sapiens Sialic acid-binding Ig-like lectin 9 Proteins 0.000 description 1
- 101001018021 Homo sapiens T-lymphocyte surface antigen Ly-9 Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- SQVRNKJHWKZAKO-LUWBGTNYSA-N N-acetylneuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-LUWBGTNYSA-N 0.000 description 1
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 description 1
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 101100190847 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PMP3 gene Proteins 0.000 description 1
- 108010029176 Sialic Acid Binding Ig-like Lectin 1 Proteins 0.000 description 1
- 108010029157 Sialic Acid Binding Ig-like Lectin 2 Proteins 0.000 description 1
- 108010029180 Sialic Acid Binding Ig-like Lectin 3 Proteins 0.000 description 1
- 102100027164 Sialic acid-binding Ig-like lectin 10 Human genes 0.000 description 1
- 101710143293 Sialic acid-binding Ig-like lectin 10 Proteins 0.000 description 1
- 102100029946 Sialic acid-binding Ig-like lectin 7 Human genes 0.000 description 1
- 102100029965 Sialic acid-binding Ig-like lectin 9 Human genes 0.000 description 1
- 102100032855 Sialoadhesin Human genes 0.000 description 1
- 102100033447 T-lymphocyte surface antigen Ly-9 Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 description 1
- 101710128901 Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 108010025838 dectin 1 Proteins 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 108091008915 immune receptors Proteins 0.000 description 1
- 102000027596 immune receptors Human genes 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 108010025001 leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/697,240 | 2015-04-27 | ||
| US14/697,240 US20150299255A1 (en) | 2010-11-01 | 2015-04-27 | Compositions and methods for modulating innate and adaptive immune systems |
| PCT/US2015/039555 WO2016175878A1 (en) | 2015-04-27 | 2015-07-08 | Compositions and methods for treating cancer and persistent viral infections |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018514558A JP2018514558A (ja) | 2018-06-07 |
| JP2018514558A5 true JP2018514558A5 (enExample) | 2018-10-11 |
| JP6740250B2 JP6740250B2 (ja) | 2020-08-12 |
Family
ID=57198743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017556748A Expired - Fee Related JP6740250B2 (ja) | 2015-04-27 | 2015-07-08 | がんおよび持続性ウイルス感染を処置するための組成物および方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10821151B2 (enExample) |
| EP (1) | EP3288576A4 (enExample) |
| JP (1) | JP6740250B2 (enExample) |
| CA (1) | CA2983666C (enExample) |
| WO (1) | WO2016175878A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019205279A1 (en) * | 2018-01-08 | 2020-07-30 | Susavion Biosciences, Inc. | Compositions and methods of treating cancer with glycomimetic peptides |
| CA3185526A1 (en) * | 2020-07-28 | 2022-02-03 | Laura L. Eggink | Method of treatment of neutrophil-driven inflammatory pathologies |
| WO2023183059A1 (en) * | 2022-03-24 | 2023-09-28 | Susavion Biosciences, Inc. | Method of treatment of neutrophil-driven inflammatory pathologies |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0112126D0 (en) | 2001-05-18 | 2001-07-11 | Allergene Inc | Composition |
| JP2005523891A (ja) | 2002-01-23 | 2005-08-11 | セル−サイ・コーポレーシヨン | ペプチド構築物を用いる疾患もしくは状態の治療方法 |
| WO2005087793A2 (en) * | 2004-02-05 | 2005-09-22 | The Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University | Immunostimulatory compositions and uses thereof |
| US7868158B2 (en) | 2004-07-19 | 2011-01-11 | Baylor College Of Medicine | Modulation of cytokine signaling regulators and applications for immunotherapy |
| WO2006081510A2 (en) * | 2005-01-27 | 2006-08-03 | Novartis Vaccines And Diagnostics Inc. | Methods for treating renal cell carcinoma |
| US20060257357A1 (en) * | 2005-05-10 | 2006-11-16 | Cel-Sci Corporation | Method for modulating HLA class II tumor cell surface expression with a cytokine mixture |
| US8496942B2 (en) * | 2006-12-13 | 2013-07-30 | Susavion Biosciences, Inc. | Therapeutic peptides and uses thereof |
| US8460697B2 (en) | 2006-12-13 | 2013-06-11 | Susavion Biosciences, Inc. | Pro-angiogenic peptides and uses thereof |
| US7838497B2 (en) | 2006-12-13 | 2010-11-23 | Susavion Biosciences, Inc. | Pro-angiogenic peptides |
| US7811995B2 (en) * | 2006-12-13 | 2010-10-12 | Susavion Biosciences, Inc. | Therapeutic and diagnostic peptides |
| US10350260B2 (en) * | 2015-04-27 | 2019-07-16 | Susavion Biosciences, Inc. | Compositions and methods for treating cancer and persistent viral infections |
-
2015
- 2015-07-08 JP JP2017556748A patent/JP6740250B2/ja not_active Expired - Fee Related
- 2015-07-08 WO PCT/US2015/039555 patent/WO2016175878A1/en not_active Ceased
- 2015-07-08 CA CA2983666A patent/CA2983666C/en active Active
- 2015-07-08 EP EP15891006.7A patent/EP3288576A4/en not_active Withdrawn
-
2019
- 2019-07-15 US US16/512,329 patent/US10821151B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Diefenbach et al. | Strategies for target cell recognition by natural killer cells | |
| RU2757394C2 (ru) | Композиции и способы для модуляции передачи сигнала lair | |
| JP2016527286A5 (enExample) | ||
| Bialoszewska et al. | Biological and clinical significance of human NKRP1A/LLT1 receptor/ligand interactions | |
| JP2016519068A5 (enExample) | ||
| US11484572B2 (en) | Use of HLA-B27 homodimers for cancer treatment | |
| US12383602B2 (en) | HLA-B57 open conformers | |
| JP2020519230A5 (enExample) | ||
| JP2018514558A5 (enExample) | ||
| JP7313017B2 (ja) | ＭＨＣクラスＩａオープンコンフォーマー | |
| US20150299252A1 (en) | Compositions and methods for modulating innate and adaptive immune systems | |
| US10821151B2 (en) | Compositions and methods for treating cancer and persistent viral infections | |
| Guo et al. | Critical role of Toll-like receptor signaling in NK cell activation | |
| US10350260B2 (en) | Compositions and methods for treating cancer and persistent viral infections | |
| CN112543643A (zh) | 使用可溶性cd24用于治疗获得性免疫缺陷综合征（hiv/aids）的方法 | |
| US20150299255A1 (en) | Compositions and methods for modulating innate and adaptive immune systems | |
| HK40024980A (en) | Methods of use of soluble cd24 for treating immune related adverse events in cancer therapies |